3B Blackbio DX Ltd

i found the following submission done by company in May 2013.
Summary-
Company restructured balance payment of technology transfer of euro 338712 in royalty payment of 4% of net sales upto 2033. It also recieved 20% equity held by biotools back as part of restructuring.
Considering JV was not making any significant sales in those years, it seems like they opted for yearly payment, instead of doing lumpsum at beginning.

Regarding Sales through Vivid global, company shared its position in AGM. It seems they also provide sales and marketing.
Company followed this model in Europe as well where they partnered with HSBIO exclusively.

I think the video raised good questions and it would be better to get clarity from management.

1. Is truPCR sales also covered under royalty payment?
2. What is the margin pocketed by Vivid global out of domestic sales.
3. As TRUPCR is a established name in INDIA, can they provide sales and marketing independently?

Disclosure- Invested